Kerala Ayurveda Limited

Kerala Ayurveda Limited, established in 1945 by Ayurveda Acharya Vaidyan KGK Panicker, is a pioneer in authentic Ayurvedic healing with over 80 years of heritage. Headquartered in Aluva, Ernakulam District, Kerala, India, the company operates as a public limited entity with the Corporate Identification Number (CIN) L24233KL1992PLC006592. As of March 12, 2026, Kerala Ayurveda Limited's stock was listed on the Bombay Stock Exchange under the ticker symbol 530163, with a closing price of ₹188.25. The company employs approximately 501-1,000 individuals, reflecting its substantial presence in the Ayurvedic healthcare sector. For more information, visit their official website at keralaayurveda.biz.

Kerala Ayurveda Limited's primary manufacturing facility is located in Athani, near Aluva, Ernakulam District, Kerala. This plant specializes in the production of Ayurvedic medicines, including tablets, capsules, syrups, and other dosage forms. The facility adheres to Good Manufacturing Practice (GMP) standards, ensuring the safety, purity, and efficacy of its products. (keralaayurveda.biz) The company has also expanded its operations internationally, with a wellness center and treatment facility in Fremont, California, USA, established to promote Ayurveda in the United States.

The leadership team at Kerala Ayurveda Limited comprises several key executives:

• Ramesh Vangal: Non-Executive Chairman
• Kunjupanicker Anilkumar: Whole Time Director
• Anand Subramanian: Director
• Subramaniam Krishnamurthy: Director
• Harish Kuttan Menon: Director
• Gokul Patnaik: Director
• Shilpa Kiran Gududur: Director
• Thomas Karapparambil George: Director
• Rajesh Sharma: Director
• Jyothikumari: Director

These individuals collectively guide the strategic direction and operations of Kerala Ayurveda Limited, leveraging their diverse expertise to uphold the company's commitment to authentic Ayurvedic healing.

Kerala Ayurveda Limited has made strategic efforts to expand its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. In the U.S., the company has established a wellness center and treatment facility in Fremont, California, to promote Ayurveda and cater to the growing interest in alternative medicine. While specific regulatory filings and approvals in the EU, UK, Australia, and Japan are not publicly detailed, the company's international expansion indicates a proactive approach to meeting the regulatory requirements of these markets. The focus on wellness centers and treatment facilities suggests an emphasis on providing Ayurvedic services in addition to product exports.

Kerala Ayurveda Limited has demonstrated a commitment to emerging markets by establishing a subsidiary in Singapore named Nutraveda Pte. Ltd. in June 2009. This subsidiary was incorporated to market natural and herbal value-added products globally, thereby delivering wellness and nutritional benefits to international markets. Additionally, the company's expansion into the U.S. market through the Fremont wellness center reflects a strategic move to tap into the growing interest in Ayurvedic treatments and products in North America. While specific activities in Africa, Latin America, and Southeast Asia are not detailed, the establishment of international subsidiaries and facilities indicates a strategic focus on global market penetration.

Kerala Ayurveda Limited's geographic strategy appears to be focused on both domestic consolidation and international expansion. Domestically, the company has a significant presence with numerous clinics, wellness centers, and manufacturing facilities across India. Internationally, the establishment of subsidiaries in Singapore and the U.S. indicates a strategic intent to diversify its market presence and reduce reliance on the Indian market. This diversification helps mitigate concentration risk and positions the company to leverage growth opportunities in various regions. The emphasis on wellness centers and treatment facilities aligns with the global trend towards holistic health and wellness, suggesting a forward-looking approach to market expansion.

Specific details regarding Kerala Ayurveda Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's international expansion, including the establishment of a wellness center in Fremont, California, suggests an awareness of the regulatory requirements in the U.S. market. However, without publicly accessible records, a comprehensive assessment of the company's FDA compliance status cannot be made.

Information regarding Kerala Ayurveda Limited's World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's adherence to Good Manufacturing Practice (GMP) standards at its manufacturing facility in Athani, Kerala, indicates a commitment to quality. (keralaayurveda.biz) However, without specific certifications or prequalification statuses, it is challenging to assess the company's compliance with international standards.

Kerala Ayurveda Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Athani, Kerala, is licensed by the CDSCO, ensuring compliance with national standards for Ayurvedic product manufacturing. Additionally, the company has obtained necessary approvals from state drug controllers and export No Objection Certificates (NOCs) to facilitate the export of its products. These regulatory compliances underscore the company's commitment to maintaining high-quality standards in its operations.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Kerala Ayurveda Limited by regulatory authorities. The absence of such records suggests that the company maintains a favorable regulatory standing. However, without access to detailed inspection histories, a comprehensive assessment cannot be made.

Kerala Ayurveda Limited operates in the Ayurvedic and herbal products sector, facing competition from both domestic and international companies. Domestically, competitors include companies like Himalaya Drug Company and Dabur India Limited, which have established brands and extensive distribution networks. Internationally, the company competes with global herbal product manufacturers such as Himalaya Wellness Company and Patanjali Ayurved Limited. While Kerala Ayurveda Limited holds a 100% market share in the Adaptogen category, its overall market share across all products is relatively small, indicating a niche position in the market. The company's focus on authentic Ayurvedic formulations and holistic wellness services differentiates it from competitors.

Kerala Ayurveda Limited's key differentiators include its over 80 years of heritage in authentic Ayurvedic healing, a comprehensive product portfolio encompassing over 350 classical and proprietary formulations, and a holistic approach that integrates wellness resorts, hospitals, clinics, academies, and manufacturing facilities. The company's commitment to Good Manufacturing Practice (GMP) standards and its international expansion efforts further enhance its competitive edge. These factors collectively position Kerala Ayurveda Limited as a unique player in the Ayurvedic healthcare sector.

Kerala Ayurveda Limited's current strategic direction focuses on expanding its presence in both domestic and international markets, emphasizing the integration of traditional Ayurvedic practices with modern wellness services. The establishment of wellness centers and treatment facilities in the U.S. and Singapore reflects a strategic move to tap into global markets. The company's future outlook appears to be centered on leveraging its heritage and comprehensive service offerings to become a leading global provider of Ayurvedic healthcare solutions.

Kerala Ayurveda Limited has a track record of consistent export activity, with a total export value of $22,000 USD across 40 shipments from 2022 to 2026. The company's portfolio is highly concentrated, with the top five products accounting for 100% of its exports. Notably, it holds a 100% market share in the Adaptogen category, indicating a strong position in this segment. The company's adherence to GMP standards and its international expansion efforts suggest reliability and a commitment to quality.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulations.